Significance of Durable Responses in DeLLphi-301 Trial

Joshua K. Sabari, MD, discusses how, despite the relatively small numbers of CRs and PRs in the DeLLphi-301 trial, the DOR to tarlatamab (exceeding 6 months in 59% of patients and more than 9 months in 29%) is promising, particularly considering that more than 50% of responders maintained their response at the data cutoff, indicating potential long-term benefits in this treatment setting.

EP: 1.Clinical Impressions and Therapy Goals

EP: 2.Considerations for Extended Chemoimmunotherapy

EP: 3.Prophylactic Cranial Irradiation Considerations

EP: 4.Mechanism of Action of BiTE Immunotherapy

EP: 5.Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes

Now Viewing

EP: 6.Significance of Durable Responses in DeLLphi-301 Trial

EP: 7.Expectations for PFS and OS in Relapsed/Refractory SCLC

EP: 8.Future Potential in Combination Therapies

EP: 9.Dual Maintenance With BiTE and PD-L1 Inhibitors

EP: 10.B7-H3 Mechanism and Therapeutic Potential

EP: 11.Current Practices in B7-H3 Testing

EP: 12.Interpreting IDeate-Lung02 Trial Outcomes

EP: 13.Comparing Dosing Schedules With Standard Therapies

EP: 14.Potential Synergies With T-Cell Engagers

EP: 15.Prospects in First-Line and Maintenance Settings

EP: 16.Mechanism of Action Compared With Other Alkylating Agents

EP: 17.Efficacy in Platinum-Sensitive vs Platinum-Resistant SCLC

EP: 18.Comparative Efficacy and Future Directions in SCLC Treatment

Video content above is prompted by the following:

Despite the relatively small numbers of CRs and PRs (n = 68) in DeLLphi-301, please discuss your opinion on the DOR to tarlatamab at greater than 6 months (59%) and at greater than 9 months (29%), as well as the ongoing response at data cutoff (> 50% [n = 38]) in the 2 treatment groups?

Recent Videos